3.43

3.92% -0.14

Pre-market: 3.45 0.02 +0.58%

Eledon Pharmaceuticals Inc (ELDN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Eledon Pharmaceuticals Inc stock is traded at $3.43, with a volume of 958.75K. It is down -3.92% in the last 24 hours and down -9.74% over the past month. Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

Previous Close:

$3.57

Open:

$3.61

24h Volume:

958.75K

Relative Volume:

0.70

Market Cap:

$264.75M

Revenue:

Net Income/Loss:

$-78.15M

P/E Ratio:

-4.0009

EPS:

-0.8573

Net Cash Flow:

$-68.89M

1W Performance:

-4.19%

1M Performance:

-9.74%

6M Performance:

+109.15%

1Y Performance:

+19.51%

1-Day Range:

$3.4101

$3.70

1-Week Range:

$3.38

$3.765

52-Week Range:

$1.35

$4.60

Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile

Name

Eledon Pharmaceuticals Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

949-238-8090

Address

19800 MACARTHUR BLVD., IRVINE

Employee

Twitter

Next Earnings Date

2026-05-13

Latest SEC Filings

ELDN's Discussions on Twitter

Compare ELDN vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ELDN Eledon Pharmaceuticals Inc	3.43	264.75M	0	-78.15M	-68.89M	-0.8573
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-18-25	Resumed	H.C. Wainwright	Buy
Jan-28-25	Initiated	Guggenheim	Buy
May-13-22	Resumed	Cantor Fitzgerald	Overweight
Mar-23-21	Initiated	Cantor Fitzgerald	Overweight

Eledon Pharmaceuticals Inc Stock (ELDN) Latest News

Jun 13, 2026

ELDN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Jun 13, 2026

Jun 12, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 12, 2026

Jun 10, 2026

Eledon Pharmaceuticals (ELDN) Announces Updated Results From Investigator-Initiated Trial Evaluating tegoprubart - Insider Monkey

Jun 10, 2026

10 Hot Biotech Stocks Under $5 to Buy - Insider Monkey

Jun 10, 2026

Jun 08, 2026

Eledon trial shows all 12 diabetes patients achieve insulin independence By Investing.com - Investing.com Australia

Jun 08, 2026

Eledon Pharmaceuticals (ELDN) Reports Promising Results for Tego - GuruFocus

Jun 08, 2026

Midday Stock Roundup: Eledon Up 4% on T1D Trial Results - Orange County Business Journal

Jun 08, 2026

Eledon Pharmaceuticals stock surges on diabetes trial results By Investing.com - Investing.com South Africa

Jun 08, 2026

Eledon Pharmaceuticals stock surges on diabetes trial results - Investing.com

Jun 08, 2026

Eledon Pharmaceuticals (ELDN) Reports Promising Results for Tegoprubart in T1D Trials - GuruFocus

Jun 08, 2026

Eledon trial shows all 12 diabetes patients achieve insulin independence - Investing.com

Jun 08, 2026

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine - The Manila Times

Jun 08, 2026

Jun 05, 2026